Examples of using Lenalidomide in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Resume lenalidomide at Dose level -1 once daily.
As a precaution, all male patients taking lenalidomide must meet the following conditions.
Resume lenalidomide at Starting dose once daily.
Elotuzumab will be given in combination with lenalidomide, which is contraindicated during pregnancy.
Lenalidomide and dexamethasone administration could continue until progression or unacceptable toxicity.
People also translate
Strictly follow all instructions provided to you by your physician orpharmacist while using Lenalid Lenalidomide.
A majority of lenalidomide is eliminated through urinary excretion.
MorphoSys Presents First Safety and Efficacy Data of MOR208 in Combination with Lenalidomide from a Phase 2 Study in DLBCL.
Pregnancy warning Lenalidomide is structurally related to thalidomide.
Patients with a historyof severe rash associated with thalidomide treatment should not receive lenalidomide.
Lenalidomide induced in monkeys malformations similar to those described with thalidomide see section 5.3.
Patients with a historyof severe rash associated with thalidomide treatment should not receive lenalidomide.
Interrupt lenalidomide treatment and conduct the CBC at least every 7 days Resume lenalidomide at next lower level Dose Level -2, -3, -4 or -5.
There was no increase in peripheralneuropathy observed with long term use of lenalidomide for the treatment of newly diagnosed multiple myeloma.
After initiation of lenalidomide therapy, subsequent lenalidomide dose modification in renally impaired patients should be based on individual patient treatment tolerance, as described above.
It is used in adults who have received at least two prior therapies,including both lenalidomide and bortezomib, and whose disease progressed after the last treatment.
It is used in people whose myeloma has become worse,despite having received at least two other kinds of treatment, including the medicines lenalidomide and bortezomib.
Solid tumours were reported in 2.5% and 1.9% of Empliciti combined with lenalidomide and dexamethasone and lenalidomide and dexamethasone treated patients.
Lenalidomide treatment in myelodysplastic syndromes patients is associated with a higher incidence of grade 3 and 4 neutropenia and thrombocytopenia compared to patients on placebo see section 4.8.
We are very encouraged by our most recent clinical data from theongoing L-MIND study of MOR208 in combination with lenalidomide in relapsed or refractory diffuse large B-cell lymphoma DLBCL.
For patients older than 75 years of age treated with lenalidomide in combination with dexamethasone, the starting dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each 28-day treatment cycle.
Lenalidomide works in a number of different ways: it blocks the development of abnormal cells, prevents the growth of blood vessels within tumours and also stimulates specialised cells of the immune system to attack the abnormal cells.
Cases of AML have been observed in clinical trials of newlydiagnosed multiple myeloma in patients taking lenalidomide treatment in combination with melphalan or immediately following high dose melphalan and ASCT see section 4.4.
The combination of lenalidomide with low dose dexamethasone in newly diagnosed multiple myeloma patients is associated with a decreased incidence of grade 4 neutropenia 8.5% in Rd and Rd18, compared with 15% in MPT.
This increase was not observed in clinical trials of newlydiagnosed multiple myeloma in patients taking lenalidomide in combination with low dose dexamethasone compared to thalidomide in combination with melphalan and prednisone.
The combination of lenalidomide with low dose dexamethasone in newly diagnosed multiple myeloma patients is associated with a decreased incidence of grade 3 and 4 thrombocytopenia 8.1 in Rd and Rd18 compared to 11% in MPT.
In patients with newly diagnosed multiple myeloma aged 75 years andolder who received lenalidomide, there was a higher incidence of serious adverse reactions and adverse reactions that led to treatment discontinuation see section 4.4.
KRd Kyprolis, lenalidomide and dexamethasone; Rd lenalidomide, dexamethasone; PFS progression-free survival; HR hazard ratio; CI confidence interval; IMWG International Myeloma Working Group; EBMT European blood and marrow transplantation.
In myelodysplastic syndromes patients, lenalidomide is associated with a higher incidence of grade 3 or 4 neutropenia 74.6% in lenalidomide-treated patients compared with 14.9% in patients on placebo in the Phase III study.
In patients with multiple myeloma, the combination of lenalidomide with dexamethasone is associated with an increased risk of venous thromboembolism(predominantly deep vein thrombosis and pulmonary embolism) and arterial thromboembolism predominantly myocardial infarction and cerebrovascular event.